Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Thyroid Cancer, Papillary 1Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Nivolumab 2Bortezomib 2vatalanib 1tovorafenib 1tipifarnib 1spartalizumab 1sargramostim 1romidepsin 1pentetreotide 1pasireotide 1milademetan 1fludarabine phosphate 1entrectinib 1entinostat 1dabrafenib 1cobimetinib 1avelumab 1alectinib 1aldesleukin 1Vemurafenib 1Taxes 1Specimen Handling 1Rose Bengal 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1PLX8394 1Molecular Diagnostic Techniques 1Microscopy, Electron 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Famotidine × Endocrine × Clear all
NCT00451880 2011-10-13

Study of XL281 in Adults With Solid Tumors

Exelixis

Phase 1 Completed
180 enrolled
DermatologicEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡